In melanoma, recent clinical trials have shown that the pan-Trk inhibitor entrectinib is has a therapeutic impact in Trk-fusion melanoma [11], but the mechanism is uncertain as entrectinib can also inhibit other signaling molecules, such as ROS-1 or ALK. This evidence concerns the gene ROS1 and melanoma.